相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery of a novel pseudo beta-hairpin structure of N-truncated amyloid-beta for use as a vaccine against Alzheimer's disease
Preeti Bakrania et al.
MOLECULAR PSYCHIATRY (2022)
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
THE COMPLEXITY OF ALZHEIMER'SDISEASE: AN EVOLVING PUZZLE
Camilla Ferrari et al.
PHYSIOLOGICAL REVIEWS (2021)
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tau immunotherapy is associated with glial responses in FTLD-tau
Boram Kim et al.
ACTA NEUROPATHOLOGICA (2021)
Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
G. Caleb Alexander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Development of immunoprecipitation-two-dimensional liquid chromatography-mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients
Sebastiaan Bijttebier et al.
JOURNAL OF CHROMATOGRAPHY A (2021)
Microglial activation and tau propagate jointly across Braak stages
Tharick A. Pascoal et al.
NATURE MEDICINE (2021)
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Tien Dam et al.
NATURE MEDICINE (2021)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
Stephen Salloway et al.
NATURE MEDICINE (2021)
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease
Petr Novak et al.
NATURE AGING (2021)
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease
David Gate et al.
NATURE (2020)
Advances and considerations in AD tau-targeted immunotherapy
Alice Bittar et al.
NEUROBIOLOGY OF DISEASE (2020)
Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau
Nadine Ait-Bouziad et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model
Shoutang Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease
Joseph W. Lewcock et al.
NEURON (2020)
Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease
Malcolm Roberts et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Marie Albert et al.
BRAIN (2019)
Alzheimer disease and aducanumab: adjusting our approach
Dennis J. Selkoe
NATURE REVIEWS NEUROLOGY (2019)
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
Lisa Vermunt et al.
ALZHEIMERS & DEMENTIA (2019)
Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression
Xinyi Wang et al.
CELL RESEARCH (2019)
Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease
Michael Ewers et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Justin M. Long et al.
CELL (2019)
Diagnosis and Management of Dementia: Review
Zoe Arvanitakis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
Francesco Panza et al.
ANNALS OF NEUROLOGY (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise
Christopher H. van Dyck
BIOLOGICAL PSYCHIATRY (2018)
Gut Microbiota is Altered in Patients with Alzheimer's Disease
Zhen-Qian Zhuang et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Tau-targeting therapies for Alzheimer disease
Erin E. Congdon et al.
NATURE REVIEWS NEUROLOGY (2018)
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S. Honig et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Joseph W. Arndt et al.
SCIENTIFIC REPORTS (2018)
FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease
Petr Novak et al.
ALZHEIMERS RESEARCH & THERAPY (2018)
Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly
Annamaria Cattaneo et al.
NEUROBIOLOGY OF AGING (2017)
Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?
A. Claudio Cuello
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Gut microbiome alterations in Alzheimer's disease
Nicholas M. Vogt et al.
SCIENTIFIC REPORTS (2017)
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Elizabeth Head et al.
CURRENT ALZHEIMER RESEARCH (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy
Francesco Panza et al.
IMMUNOTHERAPY (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
How neuroinflammation contributes to neurodegeneration
Richard M. Ransohoff
SCIENCE (2016)
Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease
Myles R. Minter et al.
SCIENTIFIC REPORTS (2016)
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease
Michael G. Agadjanyan et al.
ALZHEIMERS & DEMENTIA (2015)
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer's Disease Model
Yaming Wang et al.
CELL (2015)
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Joseph Butchart et al.
NEUROLOGY (2015)
Primary age-related tauopathy (PART): a common pathology associated with human aging
John F. Crary et al.
ACTA NEUROPATHOLOGICA (2014)
Amyloid and tau in the brain in sporadic Alzheimer's disease: defining the chicken and the egg
Cheryl A. Hawkes et al.
ACTA NEUROPATHOLOGICA (2014)
Toll-Like Receptors in Alzheimer's Disease: A Therapeutic Perspective
Maria E. Gambuzza et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model
Eva Kontsekova et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease A Genome-Wide Association Study
Adam C. Naj et al.
JAMA NEUROLOGY (2014)
Immunotherapy in Alzheimer's Disease: Do We Have All the Pieces of the Puzzle?
Marie Sarazin et al.
BIOLOGICAL PSYCHIATRY (2013)
Immunotherapy for Alzheimer's disease: hoops and hurdles
Cynthia A. Lemere
MOLECULAR NEURODEGENERATION (2013)
Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
Bernd Bohrmann et al.
JOURNAL OF ALZHEIMERS DISEASE (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
Bengt Winblad et al.
LANCET NEUROLOGY (2012)
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Iryna Benilova et al.
NATURE NEUROSCIENCE (2012)
OPINION Immunotherapy for Alzheimer disease-the challenge of adverse effects
Yu-Hui Liu et al.
NATURE REVIEWS NEUROLOGY (2012)
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
David M. Holtzman et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Immunotherapy for Alzheimer's disease
D. Morgan
JOURNAL OF INTERNAL MEDICINE (2011)
Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-β Immunotherapy
Allan Wang et al.
JOURNAL OF NEUROSCIENCE (2011)
Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)
F. Mangialasche et al.
LANCET NEUROLOGY (2011)
Biomarkers in frontotemporal lobar degenerations-Progress and challenges
William T. Hu et al.
PROGRESS IN NEUROBIOLOGY (2011)
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease
Erik Portelius et al.
ACTA NEUROPATHOLOGICA (2010)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack et al.
LANCET NEUROLOGY (2010)
Alzheimer's disease: clinical trials and drug development
Francesca Mangialasche et al.
LANCET NEUROLOGY (2010)
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Bruno Vellas et al.
CURRENT ALZHEIMER RESEARCH (2009)
Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests
K. A. Bates et al.
MOLECULAR PSYCHIATRY (2009)
Long-term effects of Aβ42 immunisation in Alzheimer's disease:: follow-up of a randomised, placebo-controlled phase I trial
Clive Holmes et al.
LANCET (2008)
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements
Ayodeji A. Asuni et al.
JOURNAL OF NEUROSCIENCE (2007)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Increased T-cell reactivity and elevated levels of CD8(+) memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: Implications for immunotherapy
Katharina Schindowski et al.
NEUROMOLECULAR MEDICINE (2007)
Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease
Agneta Nordberg
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2006)
IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor
R Deane et al.
JOURNAL OF NEUROSCIENCE (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
S Gilman et al.
NEUROLOGY (2005)
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease
I Ferrer et al.
BRAIN PATHOLOGY (2004)
Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies
MD Kirkitadze et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
分享论文
